Understanding the biology of oral cancer

Medical Science Monitor

Volumn 8, Issue 11, 2002, Pages

  Das, Bibhu R ^a,b   Nagpal, Jatin K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b SRL Ranbaxy Ltd   (India)

Author keywords

Diagnosing cancer; Oral cancer; Therapy of cancer; Tumor progression

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; FLAVOPIRIDOL; FLUOROURACIL; ONYX 015; PROTEIN P16; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CELL IMMORTALIZATION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIET; EARLY DIAGNOSIS; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE THERAPY; GENETIC STABILITY; GENETIC SUSCEPTIBILITY; HUMAN; METASTASIS; MOUTH CARCINOMA; MOUTH HYGIENE; ONCOGENE; PRECANCER; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; REVIEW; SQUAMOUS CELL CARCINOMA; TOBACCO; TUMOR SUPPRESSOR GENE; VIRUS INFECTION; WART VIRUS; DISEASE COURSE; MOUTH TUMOR; PATHOLOGY;

CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; HUMANS; MOUTH NEOPLASMS;

EID: 0036858555     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Fearon ER. Vogelstein B: A genetic model for colorectal tumorigenesis. Cell, 1990; 6: 759-767
2. Hahn WC, Counter CM, Lundberg AS et al: Creation of human tumor cells with defined genetic elements. Nature, 1999; 400: 464-468
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell, 2000; 100: 57-70
4. Gupta PC, Pindborg JJ, Mehta FS: Comparison of carcinogenicity of betel quid with and without tobacco: An epidemiologic review. Ecology of Disease, 1982; 1: 213-219
5. Paterson IC, Eveson JW, Prime SS: Molecular changes in oral cancer may reflect etiology and ethnic origin. Oral Oncol Eur J Cancer, 1996; 32B: 150-153
6. Paz JB, Cook N, Odom-Maryon T et al: Human papillomavirus (HPV) in head and neck cancer: An association of HPV-16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer, 1997; 9: 595-604
7. Daftary DK, Murti PR, Bhonsle RB et al: Risk factors and risk markers for oral cancer in high incidence areas of the world. In: Johnson NW, editor. Oral Cancer, Vol. 2. Cambridge University Press. Cambridge, 1991; 29-63
8. International Agency for Research on Cancers: Tobacco habits other than smoking: Betel quid and areca nut chewing and some related nitrosamiens. In: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon. IARC, 1985: 37
9. International Agency for Research on Cancers: Tobacco smoking. In: IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans. Lyon IARC, 1986; 38
10. Merchant A, Husain SSM, Hosain M et al: Paan without tobacco: An independent risk factor for oral cancer. Int J Cancer, 2000; 86: 128-131
11. Ramchandani AG, D'Souza AV, Borges AM et al: Evaluation of carcinogenic / co-carcinogenic activity of a common chewing product, Pan Masala, in mouse skin, stomach and esophagus. Int J Cancer, 1998; 75: 225-232
12. Saranath D: Integrated biology and molecular pathology of oral cancer. In: Saranath D ed. Contemporary Issues in Oral Cancer. Oxford University Press, New Delhi, 2000; 30-71
13. Nagpal JK, Patnaik S, Das BR: Prevalence of high-risk Human Papilloma Virus Types and its association with p53 Codon-72 polymorphism in tobacco addicted Oral Squamous Cell Carcinoma (OSCC) patients of Eastern India. Int J Cancer, 2002; 97: 649-653
14. International Agency for Research on Cancers: Alcohol drinking. In: IARC Monographs on the Evaluation of Carcinogenic Risk to Humans. Lyon, IARC, 1988; 44
15. Franceschi S, Levi F, Vecchia CL et al: Comparison of the effect of smoking and alcohol drinking between oral and pharyngeal cancer. Int J Cancer, 1999; 83: 1-4
16. Harty LC, Capsraso NE, Hayes RB et al: Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst, 1997; 89: 1698-1705
17. Notani PN, Jayant K: Role of diet in upper aerodigestive tract cancer. Nutr Cancer, 1987; 10: 103-113
18. Negri E, Franceschi S, Bosetti C et al: Selected micronutrients and oral and pharyngeal cancer. Int J Cancer, 2000; 86: 122-127
19. Mao EJ, Smith CJ: Detection of Epstein-Barr virus (EBV) DNA by the polymerase chain reaction (PCR) in oral mucosa of healthy individuals and patients with squamous cell carcinoma. J Oral Pathol Med, 1993; 22: 12-17
20. Schepman KP, van der Waal I: A proposal for classification and staging system for oral leukoplakia: a preliminary study. Oral Oncol Eur J Cancer, 1995; 31B: 396-398
21. Mehta FS, Hamner III JE: eds. In: Tobacco-Related Oral Mucosal Lesions and Conditions in India. Basic Dental Research Unit, TIFR, Mumbai, 1993
22. Silverman S, Gorsky M, Lozada F: Oral leukoplakia and malignant transformation: A follow-up study. Cancer, 1984; 53: 563-568
23. Kramer IRH, El-Lablan D, Lee KW: The clinical features and risk of malignant transformation in sublingual keratosis. Br Dent J, 1978; 144: 171-180
24. Vas'Kovaskaia GP, Abramova EI: Cancer development from lichen planus on the oral and labial mucosa. Stomatologiia (Mosk), 1981; 40: 46-48
25. Pindborg JJ, Murti PR, Bhonsle RB et al: Oral submocous fibrosis as pre-cancerous condition. Scand J Dent Res, 1984; 92: 224-229
26. Alvi A, Myers EN, Johnson JT: Cancer of the oral cavity. In: Myers EN, Suen JY, editors. Cancer of the Head and Neck. 3rd Edition. Philadelphia: Mosby, 1996; 321-360
27. American Joint Committee for Cancer Staging and End-Results Reporting. Chicago: American Joint Committee on Cancer, 1998
28. Saranath D, Panchal RG, Nair R et al: Amplification and overexpression of Epidermal Growth Factor Receptor gene in human oropharyngeal cancer. Oral Oncol Eur J Cancer, 1992; 29B: 139-143
29. Grandis JR, Tweardy D: Elevated levels of transforming growth £actor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res, 1993; 53: 3579-3584
30. Grandis JR, Melhem MF, Gooding WE et al: Levels of TGE-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst, 1998; 90(11): 824-832
31. He Y, Zeng Q, Drenning SD et al: Inhibition of Human Squamous Cell Carcinoma Growth in Vivo by Epidermal Growth Factor Receptor Antisense RNA Transcribed from the U6 Promoter, 1998; 90(14): 1080-1087
32. Zeng Q, Smith DC, Suscovich TJ et al: Determination of intermediate biomarker expression levels by quantitative reverse transcription - Polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res, 2000; 6: 2245-2251
33. Rubin GJ, Tweardy DJ, Melhem MF: Asynchronous modulation of transforming growth factor-a and epidermal growth factor receptor protein expression in progression of premalignant lesions in head and neck squamous cell carcinoma. Clin Cancer Res, 1998; 4: 13-20
34. Saranath D, Panchal RG, Nair R et al: Oncogene amplification in squamous cell carcinoma of the oral cavity. Jpn J Cancer Res, 1989; 80: 430-437
35. Saranath D, Change SE, Bhoite LT et al: High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco related human oral carcinomas in India. Br J Cancer, 1991; 63: 573-578
36. Xu J, Gimenez-Conti IB, Cunningham JE et al: Alterations of p53, cyclin DI, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer, 1998; 83: 204-12
37. Leonard JH, Kearsley JH, Chenevix-Trench G, Hayward NK: Analysis of gene amplification in head and neck squamous cell carcinoma. Int J Cancer, 1991; 48: 511-515
38. Jares P, Fernandez PL, Campo E et al: PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res, 1994; 54: 4813-4817
39. Bartkova J, Lukas J, Muller H et al: Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res, 1995; 55: 949-956
40. Kyomoto R, Kumazawa H, Toda Y et al: Cyclin D1 gene amplification is a more potent prognostic factor than its protein overexpression in human head and neck squamous cell carcinoma. Int J Cancer, 1997; 74: 576-581
41. Izzo JG, Papadimitrakopoulou VA, Li XQ et al: Dysregulated cyclin D1 expression early in head and neck tumorigenesis: In vivo evidence for an association with subsequent gene amplification. Oncogene, 1998; 17: 2313-2522
42. Meredith SD, Levine PA, Burns JA et al: Chromosome 11q13 amplification in head and neck squamous cell carcinoma: Association with poor prognosis. Arch Otolaryngol Head Neck Surg, 1995; 121: 790-794
43. Akervall JA, Jin Y, Wennerberg JP et al: Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer, 1995; 76: 853-859
44. Grandis JR, Drenning SD, Zeng Q et al: Constitutive activation of Stat-3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA, 2000; 97: 4227-4232
45. Nagpal JK, Mishra R, Das BR: Activation of Stat-3 as one of the early events in Tobacco Chewing Mediated Oral Carcinogenesis. Cancer, 2002; 94(9): 2393-2400
46. Weinberg RA: Tumor suppressor genes. Science, 1991; 254: 1138-1146
47. Levine AJ: Tumor suppressor genes. Annu Rev Biochem, 1993; 62: 623-651
48. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell, 1997; 88: 323-331
49. Boyle JO, Hakim J, Koch W et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res, 1993; 53: 4477-4480
50. Caamano J, Zhang SY, Rosvold EA et al: p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol, 1993; 142: 1131-1139
51. Baral RN, Patnaik S, Das BR: Co-overexpression of p53 and c-myc proteins is linked with advance stages of betel and tobacco related oral squamous cell carcinoma from Eastern India. Eur J Oral Sci, 1998; 106(5): 907-913
52. Saranath D, Tandle AT, Teni TR et al: p53 inactivation in chewing tobacco induced oral cancers and leukoplakias from India. Oral Oncol Eur J Cancer, 1999; 35: 242-250
53. Brennan JA, Boyle JO, Koch WM et al: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med, 1995; 332: 712-717
54. Ralhan R, Nath N, Agarwal S et al: Circulating p53 antibodies as early markers of oral cancer: Correlation with p53 alterations. Clin Cancer Res, 1998; 4: 2147-2152
55. Saranath D, Tandle AT, Deo MG et al: Loss of p53 as a biomarker of high risk leukoplakias, Indian J Biochem Biophys, 1997; 34: 266-273
56. Patnaik S, Nayak BK, Das BR: Rearrangement in the coding and 5′ region of p53 gene in human oral tumours, 1UBMB. Life, 1999; 48(3): 305-309
57. Reed A, Califano J, Cairns P et al: High frequency of p16 (CDKN1/MTS-1/1NK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res, 1996; 56: 3630-3633
58. Papadimitrakopoulou V, Izzo J, Lippman SM et al: Frequent inactivation of p16NK4a in oral premalignant lesions. Oncogene, 1997; 14: 1799-1803
59. Emilion G, Langdon JD, Speight P, Partridge M: Frequent gene deletions in potentially malignant oral lesions. Br J Cancer, 1996; 73: 809-813
60. Okami K, Reed AL, Cairns P et al: Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene, 1999; 18: 3541-3545
61. Boland RC, Thibodeau SN, Hamilton SR et al: A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res, 1998; 58: 5248-5257
62. Adamson R, Jones AS, Field JK: Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. Oncogene, 1994; 9: 2077-2082
63. Nawroz H, van der Riet P, Hruban RH et al: Allelotype of head and neck squamous cell carcinoma. Cancer Res, 1994; 54: 1152-1155
64. Ah-See KW, Cooke TG, Pickford IR et al: An allelotype of squamous carcinoma of the head and neck using microsatellite markers. Cancer Res, 1994; 54: 1617-1621
65. El-Naggar AK, Kenneth H, Batsakis JG et al: Sequential loss of heterozygosity at microsatellite motifs in preinvasive and invasive head and neck squamous carcinoma. Cancer Res, 1995; 55: 2656-2659
66. Mao L, Lee JS, Fan YH et al: Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Medicine, 1996; 6: 682-685
67. Mao L, El-Naggar AK, Fan YH, Hong WK: Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res, 1996; 56: 5600-5604
68. Miyoshi Y, Tsukinoki K, Imaizumi T et al: Telomerase activity in oral cancer. Oral Oncol, 1999; 35: 283-289
69. Patel MM, Patel DD, Parekh LJ et al: Evaluation of telomerase activation in head and neck cancer. Oral Oncol, 1999; 35: 510-515
70. Califano J, Ahrendt SA, Meininger G et al: Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res, 1996; 56: 5720-5722
71. Brennan JA, Mao L, Hruban RH et al: Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med, 1995; 332: 429-435
72. Califano J, Riet P, Westra W et al: Genetic progression model for head and neck cancer: Implications for field cancerization Cancer Res, 1996; 56: 2488-2492
73. Van Houten VMM, Tabor MP, van der Brekel MWM et al: Molecular assay for the diagnosis of minimal residual head and neck cancer: Methods, reliability, pitfalls and solutions. Clin Cancer Res, 2000; 6: 3803-3816
74. Lee JJ, Hong WK, Hiltelman WN et al: Predicting cancer development in oral leukoplakia: Ten years of translational research. Clin Cancer Res, 2000; 6: 1702-1710
75. Salesiotis AN, Callen KJ: Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: Evolution of a model beyond TNM staging. Curr Opin Oncol, 2000; 12: 229-239
76. Hayes DF, Bast RC, Desch CE et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst, 1996; 88(20): 1456-1466
77. Partrige M, Li SR, Pateromichelakis S et al: Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res, 2000; 6: 2718-2725
78. Sudbo J, Kildal W, Risberg B et al: DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med, 2001; 344: 1270-1278
79. Lo YM, Chan LY, Lo KW et al: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 1999; 59: 1188-1191
80. Capone RB, Pai SI, Koch WM et al: Detection of quantification of human papilloma virus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res, 2000; 6: 4171-4175
81. Nathan CA, Franklin S, Abreo FW et al: Analysis of surgical margins with the molecular marker el F4E: A prognostic factor in patients with head and neck cancer. J Clin Oncol, 1999; 17: 2909-2914
82. Shinohara M, Nakamura S, Sasaki M et al: Expression of integrins in squamous cell carcinoma of the oral cavity. Am J Clin Pathol. 1999; 111: 75-88
83. Yellin SA, Davidson BJ, Pinto JF et al: Relationship of glutathione and glutathione-S-transferase to cisplatin sensitivity in human head and neck squamous carcinoma cell lines. Cancer Lett. 1994; 85: 223-232
84. Nair MK, Sankaranarayanan R, Padmanabhan TK: Evaluation of the role of radiotherapy in the management of carcinoma of the buccal mucosa. Cancer, 1988; 61: 1326-1331
85. Forastiere A, Koch W, Trotti A, Sidransky D: Head and Neck Cancer, 345(26): 1890-1900
86. Mendenhall WM, Amdur RJ, Siemann DW et al: Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck. Curr Opin Oncol, 2000; 12: 207-214
87. Stevens KR Jr, Britisch A, Moss WT et al: High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys, 1994; 29: 687-698
88. Horiot JC, Le Fur R, N'Guyen T et al: Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol, 1992; 25: 231-241
89. Pinto L, Canary P, Araujo CM et al: Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma, Int J Radiat Oncol Biol Phys, 1991; 21: 557-562
90. Datta NR, Choudhry AD, Gupta S et al: Twice a day versus once a day radiation therapy in head and neck cancer. Int J Radiat Oncol Biol Phys, 1989; 17(Suppl 1): 132-133
91. Horiot JC, Bontemps I, van den Bogaert W et al: Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol, 1997; 44: 111-121
92. Lee DJ, Cosmatos D, Marcial VA et al: Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinoma. Int J Radiat Oncol Biol Phys, 1995; 32: 567-576
93. van den Bogaert W, van der Schueren E, Horiot JC et al: Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int J Radiat Oncol Biol Phys, 1986; 12: 587-591
94. Lee D, Pajak T, Stetz J et al: A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: A RTOG randomized study (#79-04). Int J Radiat Oncol Biol Phys. 1989; 16: 465-470
95. Practice Guidelines for Squamous Cell Cancers of the Head and Neck. Philadelphia: National Comprehensive Cancer Network. 2000
96. Garewal H: Chemoprevention of oral cancer. Beta-carotene and vitamin E in leukoplakia. Eur J Cancer Prev, 1994: 3: 101-107
97. Le Q, Dawson MI, Soprano DR, Soprano KJ: Modulation of retinox acid receptor function alters the growth inhibitory response of oral SCC cells to retoids. Oncogene, 2000; 19: 1457-1465
98. Sun SY, Yue P, Mao L et al: Identification of receptor selection retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res, 2000; 6: 1563-1573
99. Benner SE, Winn RJ, Lippman SM et al: Regression of oral leukoplakia with alpha-tocopherol: A community clinical oncology program chemoprevention study. J Natl Cancer Inst, 1993; 85: 44-47
100. Brizel DM, Albers ME, Fisher SR et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med, 1998; 338: 1798-1804
101. Robbins KT, Kumar P, Regine WF et al: Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: The Memphis experience. Int J Radiat Oncol Biol Phys, 1997; 38: 263-271
102. Khuri FR, Nemunaitis J, Ganly I et al: A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med, 2000; 6(8): 879-885
103. Heise CC, William AM, Xue S et al: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces anti-tumoral efficacy. Cancer Res, 1999; 59: 2623-2628
104. Rocco JN, Li D, Liggett WH et al: p16 INKYA adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res, 1998; 4: 1697-1704
105. Liu TJ, Zhang WW, Taylor DL et al: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via recombinant adenovirus. Cancer Res, 1994; 54: 3662-3667
106. Mendelsohn J, Shin DM, Donato N et al: A phase I study of chimerized anti-epidermal growth factor receptor (EGFr) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck squamous cell carcinoma (SCC). Prog Proc Am Soc Clin Oncol, 1999; 18: 389a. abstract
107. Ezekiel MP, Bonner JA, Robert F et al: Phase I trial of chimerized anti-epidermal growth factor receptor (anti-EGFr) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies. Prog Proc Am Soc Clin Oncol, 1999; 18: 388a
108. Patel V, Senderowicz AM, Pinto D Jr et al: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest, 1998; 102: 1674-1681
109. Pindborg JJ: In Oral Cancer and Precancer. John Wright and Sons Ltd. Bristol, 1980
110. Xie X, Clausen OP, De Angelis P et al: The prognostic value of spontaneous apoptosis. Bax, Bc-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer, 1999; 86: 913-920
111. Bova RJ, Quinn DI, Nankervis JS et al: Cyclin D1 and p161NK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res, 1999; 5: 2810-2819
112. Gleich LL, Li YQ, Biddinger PW et al: The loss of heterozygosity in retinoblastoma and p53 suppressor genes as a prognostic indicator for head and neck cancer. Laryngoscope, 1996; 106: 1378-1381
113. Koch WM, Brennan JA, Zahurak M et al: p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst, 1996; 88: 1580-1586
114. Field JK, Spandidos DA, Steil PM et al: Elevated expression of c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene, 1989; 4: 1463-1468
115. Lazar AD, Winter MR, Nogueira CP et al: Loss of heterozygosity at 11q23 in squamous cell carcinoma of the head and neck is associated with recurrent disease. Clin Cancer Res, 1998; 4: 2787-2793